Kirti Shukla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kirti Shukla has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Wiemann
Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
7 shared publications - Aleksandra Balwierz
Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
3 shared publications Cindy Körner
Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
3 shared publicationsHadas Cohen-Dvashi
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
3 shared publicationsMoshit Lindzen
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
3 shared publicationsNir Ben-Chetrit
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
3 shared publications
Latest Publications
- Open Access
- 4 August 2018
- Published by Taylor & Francis in RNA Biology
- Vol. 15 (8) , 1-11
Functional role of circular RNAs in cancer development and progression
Circular RNAs (circRNAs) are a large class of endogenously expressed non-coding RNAs formed by covalently closed loops through back-splicing. High throughput sequencing technologies have identified thousands of circRNAs with high sequence conservation and cell type specific expression in eukaryotes. CircRNAs play multiple important roles in cellular physiology functioning as miRNA sponges, transcriptional regulators, RBP binding molecules, templates for protein translation, and immune regulators. In a clinical context, circRNAs expression is correlated with patient’s clinicopathological features in cancers including breast, liver, gastric, colorectal, and lung cancer. Additionally, distinct properties of circRNAs, such as high stability, exonuclease resistance, and existence in body fluids, show promising role for circRNAs as molecular biomarkers for tumor diagnosis, non-invasive monitoring, prognosis, and therapeutic intervention. Therefore, it is critical to further understand the molecular mechanism underlying circRNAs interaction in tumors and the recent progress of this RNA species in cancer development. In this review, we provide a detailed description of biological functions, molecular role of circRNAs in different cancers, and its potential role as biomarkers in a clinical context.
- 4 August 2018
- Published by Taylor & Francis in RNA Biology
- Vol. 15 (8) , 1-11
Open AccessFunctional role of circular RNAs in cancer development and progression
Circular RNAs (circRNAs) are a large class of endogenously expressed non-coding RNAs formed by covalently closed loops through back-splicing. High throughput sequencing technologies have identified thousands of circRNAs with high sequence conservation and cell type specific expression in eukaryotes. CircRNAs play multiple important roles in cellular physiology functioning as miRNA sponges, transcriptional regulators, RBP binding molecules, templates for protein translation, and immune regulators. In a clinical context, circRNAs expression is correlated with patient’s clinicopathological features in cancers including breast, liver, gastric, colorectal, and lung cancer. Additionally, distinct properties of circRNAs, such as high stability, exonuclease resistance, and existence in body fluids, show promising role for circRNAs as molecular biomarkers for tumor diagnosis, non-invasive monitoring, prognosis, and therapeutic intervention. Therefore, it is critical to further understand the molecular mechanism underlying circRNAs interaction in tumors and the recent progress of this RNA species in cancer development. In this review, we provide a detailed description of biological functions, molecular role of circRNAs in different cancers, and its potential role as biomarkers in a clinical context.
- Open Access
- 28 September 2017
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 45 (22) , 12681-12699
Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone
Crosstalk between growth factors (GFs) and steroid hormones recurs in embryogenesis and is co-opted in pathology, but underlying mechanisms remain elusive. Our data from mammary cells imply that the crosstalk between the epidermal GF and glucocorticoids (GCs) involves transcription factors like p53 and NF-κB, along with reduced pausing and traveling of RNA polymerase II (RNAPII) at both promoters and bodies of GF-inducible genes. Essentially, GCs inhibit positive feedback loops activated by GFs and stimulate the reciprocal inhibitory loops. As expected, no alterations in DNA methylation accompany the transcriptional events instigated by either stimulus, but forced demethylation of regulatory regions broadened the repertoire of GF-inducible genes. We report that enhancers, like some promoters, are poised for activation by GFs and GCs. In addition, within the cooperative interface of the crosstalk, GFs enhance binding of the GC receptor to DNA and, in synergy with GCs, promote productive RNAPII elongation. Reciprocally, within the antagonistic interface GFs hyper-acetylate chromatin at unmethylated promoters and enhancers of genes involved in motility, but GCs hypoacetylate the corresponding regions. In conclusion, unmethylated genomic regions that encode feedback regulatory modules and differentially recruit RNAPII and acetylases/deacetylases underlie the crosstalk between GFs and a steroid hormone.
- 28 September 2017
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 45 (22) , 12681-12699
Open AccessEpigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone
Crosstalk between growth factors (GFs) and steroid hormones recurs in embryogenesis and is co-opted in pathology, but underlying mechanisms remain elusive. Our data from mammary cells imply that the crosstalk between the epidermal GF and glucocorticoids (GCs) involves transcription factors like p53 and NF-κB, along with reduced pausing and traveling of RNA polymerase II (RNAPII) at both promoters and bodies of GF-inducible genes. Essentially, GCs inhibit positive feedback loops activated by GFs and stimulate the reciprocal inhibitory loops. As expected, no alterations in DNA methylation accompany the transcriptional events instigated by either stimulus, but forced demethylation of regulatory regions broadened the repertoire of GF-inducible genes. We report that enhancers, like some promoters, are poised for activation by GFs and GCs. In addition, within the cooperative interface of the crosstalk, GFs enhance binding of the GC receptor to DNA and, in synergy with GCs, promote productive RNAPII elongation. Reciprocally, within the antagonistic interface GFs hyper-acetylate chromatin at unmethylated promoters and enhancers of genes involved in motility, but GCs hypoacetylate the corresponding regions. In conclusion, unmethylated genomic regions that encode feedback regulatory modules and differentially recruit RNAPII and acetylases/deacetylases underlie the crosstalk between GFs and a steroid hormone.
- Open Access
- 10 February 2015
- Published by Wiley in Molecular Oncology
- Vol. 9 (6) , 1106-1119
MicroRNA‐30c‐2‐3p negatively regulates NF‐κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer
Nuclear Factor kappa B (NF‐κB) signaling is frequently deregulated in a variety of cancers and is constitutively active in estrogen receptor negative (ER‐) breast cancer subtypes. These molecular subtypes of breast cancer are associated with poor overall survival. We focused on mechanisms of NF‐κB regulation by microRNAs (miRNAs), which regulate eukaryotic gene expression at the post‐transcriptional level. In a previous genome‐wide miRNA screen, we had identified miR‐30c‐2‐3p as one of the strongest negative regulators of NF‐κB signaling. Here we have uncovered the underlying molecular mechanisms and its consequences in breast cancer. In vitro results show that miR‐30c‐2‐3p directly targets both TNFRSF1A‐associated via death domain (TRADD), an adaptor protein of the TNFR/NF‐κB signaling pathway, and the cell cycle protein Cyclin E1 (CCNE1). Ectopic expression of miR‐30c‐2‐3p downregulated essential cytokines IL8, IL6, CXCL1, and reduced cell proliferation as well as invasion in MDA‐MB‐231 breast cancer cells. RNA interference (RNAi) induced silencing of TRADD phenocopied the effects on invasion and cytokine expression caused by miR‐30c‐2‐3p, while inhibition of CCNE1 phenocopied the effects on cell proliferation. We further confirmed the tumor suppressive role of this miRNA using a dataset of 781 breast tumors, where higher expression was associated with better survival in breast cancer patients. In summary we have elucidated the mechanism by which miR‐30c‐2‐3p negatively regulates NF‐κB signaling and cell cycle progression in breast cancer.
- 10 February 2015
- Published by Wiley in Molecular Oncology
- Vol. 9 (6) , 1106-1119
Open AccessMicroRNA‐30c‐2‐3p negatively regulates NF‐κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer
Nuclear Factor kappa B (NF‐κB) signaling is frequently deregulated in a variety of cancers and is constitutively active in estrogen receptor negative (ER‐) breast cancer subtypes. These molecular subtypes of breast cancer are associated with poor overall survival. We focused on mechanisms of NF‐κB regulation by microRNAs (miRNAs), which regulate eukaryotic gene expression at the post‐transcriptional level. In a previous genome‐wide miRNA screen, we had identified miR‐30c‐2‐3p as one of the strongest negative regulators of NF‐κB signaling. Here we have uncovered the underlying molecular mechanisms and its consequences in breast cancer. In vitro results show that miR‐30c‐2‐3p directly targets both TNFRSF1A‐associated via death domain (TRADD), an adaptor protein of the TNFR/NF‐κB signaling pathway, and the cell cycle protein Cyclin E1 (CCNE1). Ectopic expression of miR‐30c‐2‐3p downregulated essential cytokines IL8, IL6, CXCL1, and reduced cell proliferation as well as invasion in MDA‐MB‐231 breast cancer cells. RNA interference (RNAi) induced silencing of TRADD phenocopied the effects on invasion and cytokine expression caused by miR‐30c‐2‐3p, while inhibition of CCNE1 phenocopied the effects on cell proliferation. We further confirmed the tumor suppressive role of this miRNA using a dataset of 781 breast tumors, where higher expression was associated with better survival in breast cancer patients. In summary we have elucidated the mechanism by which miR‐30c‐2‐3p negatively regulates NF‐κB signaling and cell cycle progression in breast cancer.
- 20 January 2015
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 8 (360) , ra7
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer
Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a target of effective therapies against breast cancer. In search for similarly targetable genomic aberrations, we identified copy number gains in SYNJ2, which encodes the 5′-inositol lipid phosphatase synaptojanin 2, as well as overexpression in a small fraction of human breast tumors. Copy gain and overexpression correlated with shorter patient survival and a low abundance of the tumor suppressor microRNA miR-31. SYNJ2 promoted cell migration and invasion in culture and lung metastasis of breast tumor xenografts in mice. Knocking down SYNJ2 impaired the endocytic recycling of EGFR and the formation of cellular lamellipodia and invadopodia. Screening compound libraries identified SYNJ2-specific inhibitors that prevented cell migration but did not affect the related neural protein SYNJ1, suggesting that SYNJ2 is a potentially druggable target to block cancer cell migration.
- 20 January 2015
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 8 (360) , ra7
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer
Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a target of effective therapies against breast cancer. In search for similarly targetable genomic aberrations, we identified copy number gains in SYNJ2, which encodes the 5′-inositol lipid phosphatase synaptojanin 2, as well as overexpression in a small fraction of human breast tumors. Copy gain and overexpression correlated with shorter patient survival and a low abundance of the tumor suppressor microRNA miR-31. SYNJ2 promoted cell migration and invasion in culture and lung metastasis of breast tumor xenografts in mice. Knocking down SYNJ2 impaired the endocytic recycling of EGFR and the formation of cellular lamellipodia and invadopodia. Screening compound libraries identified SYNJ2-specific inhibitors that prevented cell migration but did not affect the related neural protein SYNJ1, suggesting that SYNJ2 is a potentially druggable target to block cancer cell migration.
- Open Access
- 3 October 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 5073
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment
Signal transduction by receptor tyrosine kinases (RTKs) and nuclear receptors for steroid hormones is essential for body homeostasis, but the cross-talk between these receptor families is poorly understood. We observed that glucocorticoids inhibit signalling downstream of EGFR, an RTK. The underlying mechanism entails suppression of EGFR’s positive feedback loops and simultaneous triggering of negative feedback loops that normally restrain EGFR. Our studies in mice reveal that the regulation of EGFR’s feedback loops by glucocorticoids translates to circadian control of EGFR signalling: EGFR signals are suppressed by high glucocorticoids during the active phase (night-time in rodents), while EGFR signals are enhanced during the resting phase. Consistent with this pattern, treatment of animals bearing EGFR-driven tumours with a specific kinase inhibitor was more effective if administered during the resting phase of the day, when glucocorticoids are low. These findings support a circadian clock-based paradigm in cancer therapy.
- 3 October 2014
- Published by Springer Nature in Nature Communications
- Vol. 5 (1) , 5073
Open AccessDiurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment
Signal transduction by receptor tyrosine kinases (RTKs) and nuclear receptors for steroid hormones is essential for body homeostasis, but the cross-talk between these receptor families is poorly understood. We observed that glucocorticoids inhibit signalling downstream of EGFR, an RTK. The underlying mechanism entails suppression of EGFR’s positive feedback loops and simultaneous triggering of negative feedback loops that normally restrain EGFR. Our studies in mice reveal that the regulation of EGFR’s feedback loops by glucocorticoids translates to circadian control of EGFR signalling: EGFR signals are suppressed by high glucocorticoids during the active phase (night-time in rodents), while EGFR signals are enhanced during the resting phase. Consistent with this pattern, treatment of animals bearing EGFR-driven tumours with a specific kinase inhibitor was more effective if administered during the resting phase of the day, when glucocorticoids are low. These findings support a circadian clock-based paradigm in cancer therapy.
- 6 August 2014
- Published by Wiley in Biologie in unserer Zeit
- Vol. 44 (4) , 258-266
microRNAs – kleine Moleküle ganz groß
- 6 August 2014
- Published by Wiley in Biologie in unserer Zeit
- Vol. 44 (4) , 258-266
microRNAs – kleine Moleküle ganz groß
- 13 May 2014
- Published by Wiley in Journal of Cellular Physiology
- Vol. 229 (12) , 2088-2105
Bradykinin Regulates Osteoblast Differentiation by Akt/ERK/NFκB Signaling Axis
Bradykinin (BK), a well known mediator of pain and inflammation, is also known to be involved in the process of bone resorption. The present study therefore evaluated the role of BK in osteoblast lineage commitment. Our data showed that BK inhibits the migration of bone marrow mesenchymal stem cells, but does not affect their viability. Moreover, BK also inhibits osteoblastic differentiation by significantly downregulating the levels of mRNAs forosteopontin,runX2,col24,osterix,osteocalcingenes and bone mineralization (P < 0.05). Further, BK was found to elicit the BK receptors (BDKR1 and BDKR2) mediated activation of ERK1/2 and Akt pathways, which finally led to the activation of NFκB. BK also promoted the osteoclast differentiation of bone marrow derived preosteoclast cells by upregulating the expression of c‐fos,NFATC1,TRAP,clcn7,cathK, andOSCARgenes and increasing TRAP activity through NFκB pathway. In conclusion, our data suggest that BK decreases the differentiation of osteoblasts with concomitant increase in osteoclast formation and thus provides new insight into the mechanism of action of BK in modulating bone resorption. J. Cell. Physiol. 229: 2088–2105, 2014.
- 13 May 2014
- Published by Wiley in Journal of Cellular Physiology
- Vol. 229 (12) , 2088-2105
Bradykinin Regulates Osteoblast Differentiation by Akt/ERK/NFκB Signaling Axis
Bradykinin (BK), a well known mediator of pain and inflammation, is also known to be involved in the process of bone resorption. The present study therefore evaluated the role of BK in osteoblast lineage commitment. Our data showed that BK inhibits the migration of bone marrow mesenchymal stem cells, but does not affect their viability. Moreover, BK also inhibits osteoblastic differentiation by significantly downregulating the levels of mRNAs forosteopontin,runX2,col24,osterix,osteocalcingenes and bone mineralization (P < 0.05). Further, BK was found to elicit the BK receptors (BDKR1 and BDKR2) mediated activation of ERK1/2 and Akt pathways, which finally led to the activation of NFκB. BK also promoted the osteoclast differentiation of bone marrow derived preosteoclast cells by upregulating the expression of c‐fos,NFATC1,TRAP,clcn7,cathK, andOSCARgenes and increasing TRAP activity through NFκB pathway. In conclusion, our data suggest that BK decreases the differentiation of osteoblasts with concomitant increase in osteoclast formation and thus provides new insight into the mechanism of action of BK in modulating bone resorption. J. Cell. Physiol. 229: 2088–2105, 2014.
- Open Access
- 21 April 2014
- Published by Wiley in The Journal of Pathology
- Vol. 233 (4) , 368-379
MicroRNA‐519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour‐suppressor genes in ER+ breast cancer
Tamoxifen is an endocrine therapy which is administered to up to 70% of all breast cancer patients with oestrogen receptor alpha (ERα) expression. Despite the initial response, most patients eventually acquire resistance to the drug. MicroRNAs (miRNAs) are a class of small non‐coding RNAs which have the ability to post‐transcriptionally regulate genes. Although the role of a few miRNAs has been described in tamoxifen resistance at the single gene/target level, little is known about how concerted actions of miRNAs targeting biological networks contribute to resistance. Here we identified the miRNA cluster, C19MC, which harbours around 50 mature miRNAs, to be up‐regulated in resistant cells, with miRNA‐519a being the most highly up‐regulated. We could demonstrate that miRNA‐519a regulates tamoxifen resistance using gain‐ and loss‐of‐function testing. By combining functional enrichment analysis and prediction algorithms, we identified three central tumour‐suppressor genes (TSGs) in PI3K signalling and the cell cycle network as direct target genes of miR‐519a. Combined expression of these target genes correlated with disease‐specific survival in a cohort of tamoxifen‐treated patients. We identified miRNA‐519a as a novel oncomir in ER+ breast cancer cells as it increased cell viability and cell cycle progression as well as resistance to tamoxifen‐induced apoptosis. Finally, we could show that elevated miRNA‐519a levels were inversely correlated with the target genes' expression and that higher expression of this miRNA correlated with poorer survival in ER+ breast cancer patients. Hence we have identified miRNA‐519a as a novel oncomir, co‐regulating a network of TSGs in breast cancer and conferring resistance to tamoxifen. Using inhibitors of such miRNAs may serve as a novel therapeutic approach to combat resistance to therapy as well as proliferation and evasion of apoptosis in breast cancer. Published by John Wiley & Sons, Ltd. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
- 21 April 2014
- Published by Wiley in The Journal of Pathology
- Vol. 233 (4) , 368-379
Open AccessMicroRNA‐519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour‐suppressor genes in ER+ breast cancer
Tamoxifen is an endocrine therapy which is administered to up to 70% of all breast cancer patients with oestrogen receptor alpha (ERα) expression. Despite the initial response, most patients eventually acquire resistance to the drug. MicroRNAs (miRNAs) are a class of small non‐coding RNAs which have the ability to post‐transcriptionally regulate genes. Although the role of a few miRNAs has been described in tamoxifen resistance at the single gene/target level, little is known about how concerted actions of miRNAs targeting biological networks contribute to resistance. Here we identified the miRNA cluster, C19MC, which harbours around 50 mature miRNAs, to be up‐regulated in resistant cells, with miRNA‐519a being the most highly up‐regulated. We could demonstrate that miRNA‐519a regulates tamoxifen resistance using gain‐ and loss‐of‐function testing. By combining functional enrichment analysis and prediction algorithms, we identified three central tumour‐suppressor genes (TSGs) in PI3K signalling and the cell cycle network as direct target genes of miR‐519a. Combined expression of these target genes correlated with disease‐specific survival in a cohort of tamoxifen‐treated patients. We identified miRNA‐519a as a novel oncomir in ER+ breast cancer cells as it increased cell viability and cell cycle progression as well as resistance to tamoxifen‐induced apoptosis. Finally, we could show that elevated miRNA‐519a levels were inversely correlated with the target genes' expression and that higher expression of this miRNA correlated with poorer survival in ER+ breast cancer patients. Hence we have identified miRNA‐519a as a novel oncomir, co‐regulating a network of TSGs in breast cancer and conferring resistance to tamoxifen. Using inhibitors of such miRNAs may serve as a novel therapeutic approach to combat resistance to therapy as well as proliferation and evasion of apoptosis in breast cancer. Published by John Wiley & Sons, Ltd. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
- Open Access
- 6 December 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e80566
Epidermal Growth-Factor – Induced Transcript Isoform Variation Drives Mammary Cell Migration
Signal-induced transcript isoform variation (TIV) includes alternative promoter usage as well as alternative splicing and alternative polyadenylation of mRNA. To assess the phenotypic relevance of signal-induced TIV, we employed exon arrays and breast epithelial cells, which migrate in response to the epidermal growth factor (EGF). We show that EGF rapidly--within one hour--induces widespread TIV in a significant fraction of the transcriptome. Importantly, TIV characterizes many genes that display no differential expression upon stimulus. In addition, similar EGF-dependent changes are shared by a panel of mammary cell lines. A functional screen, which utilized isoform-specific siRNA oligonucleotides, indicated that several isoforms play essential, non-redundant roles in EGF-induced mammary cell migration. Taken together, our findings highlight the importance of TIV in the rapid evolvement of a phenotypic response to extracellular signals.
- 6 December 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e80566
Open AccessEpidermal Growth-Factor – Induced Transcript Isoform Variation Drives Mammary Cell Migration
Signal-induced transcript isoform variation (TIV) includes alternative promoter usage as well as alternative splicing and alternative polyadenylation of mRNA. To assess the phenotypic relevance of signal-induced TIV, we employed exon arrays and breast epithelial cells, which migrate in response to the epidermal growth factor (EGF). We show that EGF rapidly--within one hour--induces widespread TIV in a significant fraction of the transcriptome. Importantly, TIV characterizes many genes that display no differential expression upon stimulus. In addition, similar EGF-dependent changes are shared by a panel of mammary cell lines. A functional screen, which utilized isoform-specific siRNA oligonucleotides, indicated that several isoforms play essential, non-redundant roles in EGF-induced mammary cell migration. Taken together, our findings highlight the importance of TIV in the rapid evolvement of a phenotypic response to extracellular signals.